Skip to main content
Premium Trial:

Request an Annual Quote

VelaDx, Thomas Jefferson Co-developing MDx for Cancer, Infectious Diseases

NEW YORK (GenomeWeb News) – Vela Diagnostics today announced a deal with Thomas Jefferson University and Hospitals to jointly develop molecular diagnostics aimed at cancer and infectious diseases.

The Singapore-based company said the two partners are currently deciding on several projects, including developing next-generation- and PCR-based assays. Using new technologies, Thomas Jefferson will help VelaDx develop and validate the assays. VelaDx will seek regulatory approval for the assays on a global basis.

"Partnering with Jefferson provides Vela Diagnostics with access to world-recognized experts in the molecular diagnostics industry," Michael Tillmann, CEO of VelaDx, said in a statement. "This is essential for the development of high quality molecular diagnostic assays in a dynamic clinical environment."

Terms of the deal were not disclosed.

VelaDx develops molecular diagnostics based on its Sentosa workflow system. In October, VelaDx and Life Technologies announced a deal under which VelaDx would develop clinical diagnostic tests on Life Tech's Ion Personal Genome Machine.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.